NovoCure Limited Operating Expenses
NovoCure Limited (NVCR) reported Operating Expenses of $153.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-07-23
- NovoCure Limited operating expenses for the quarter ending 2026-06-30 was $153.04M, a 2.43% decline year-over-year.
- NovoCure Limited operating expenses for the quarter ending 2026-03-31 was $202.55M, a 31.24% increase year-over-year.
- NovoCure Limited operating expenses for the quarter ending 2025-12-31 was $172.59M, a 9.69% decline year-over-year.
- NovoCure Limited operating expenses for the quarter ending 2025-09-30 was $158.50M, a 4.40% increase year-over-year.
- NovoCure Limited operating expenses for fiscal 2024 was $638.53M, a 4.01% increase from fiscal 2023.
- NovoCure Limited operating expenses for fiscal 2023 was $613.93M, a 19.79% increase from fiscal 2022.
- NovoCure Limited operating expenses for fiscal 2022 was $512.50M, a 10.34% increase from fiscal 2021.
- NovoCure Limited operating expenses for fiscal 2021 was $464.49M, a 29.94% increase from fiscal 2020.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $153.04M 10-Q · filed 2026-07-23 | $355.59M 10-Q · filed 2026-07-23 | $528.17M derived: sum of 3 quarters · filed 2026-07-23 | $686.67M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $202.55M 10-Q · filed 2026-04-30 | $375.13M derived: sum of 2 quarters · filed 2026-07-23 | $533.63M derived: sum of 3 quarters · filed 2026-07-23 | $690.48M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $172.59M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-23 | $331.08M derived: sum of 2 quarters · filed 2026-07-23 | $487.94M derived: sum of 3 quarters · filed 2026-07-23 | $642.27M 10-Q · filed 2026-07-23 |
| 2025-09-30 | $158.50M 10-Q · filed 2025-10-30 | $315.35M derived: sum of 2 quarters · filed 2026-07-23 | $469.69M 10-Q · filed 2025-10-30 | $660.79M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $156.85M 10-Q · filed 2026-07-23 | $311.19M 10-Q · filed 2026-07-23 | $502.30M derived: sum of 3 quarters · filed 2026-07-23 | $654.11M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $154.34M 10-Q · filed 2026-04-30 | $345.44M derived: sum of 2 quarters · filed 2026-04-30 | $497.26M derived: sum of 3 quarters · filed 2026-04-30 | $646.54M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $191.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $342.92M derived: sum of 2 quarters · filed 2026-02-26 | $492.20M derived: sum of 3 quarters · filed 2026-02-26 | $638.53M 10-K · filed 2026-02-26 |
| 2024-09-30 | $151.81M 10-Q · filed 2025-10-30 | $301.10M derived: sum of 2 quarters · filed 2025-10-30 | $447.43M 10-Q · filed 2025-10-30 | $600.38M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $149.28M 10-Q · filed 2025-07-24 | $295.62M 10-Q · filed 2025-07-24 | $448.56M derived: sum of 3 quarters · filed 2026-02-26 | $602.03M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $146.33M 10-Q · filed 2025-04-24 | $299.28M derived: sum of 2 quarters · filed 2026-02-26 | $452.75M derived: sum of 3 quarters · filed 2026-02-26 | $607.45M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $152.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $306.42M derived: sum of 2 quarters · filed 2026-02-26 | $461.11M derived: sum of 3 quarters · filed 2026-02-26 | $613.93M 10-K · filed 2026-02-26 |
| 2023-09-30 | $153.47M 10-Q · filed 2024-10-30 | $308.17M derived: sum of 2 quarters · filed 2024-10-30 | $460.98M 10-Q · filed 2024-10-30 | $603.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $154.69M 10-Q · filed 2024-07-25 | $307.51M 10-Q · filed 2024-07-25 | $450.03M derived: sum of 3 quarters · filed 2025-02-27 | $575.89M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $152.82M 10-Q · filed 2024-05-02 | $295.34M derived: sum of 2 quarters · filed 2025-02-27 | $421.20M derived: sum of 3 quarters · filed 2025-02-27 | $554.69M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $142.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $268.38M derived: sum of 2 quarters · filed 2025-02-27 | $401.87M derived: sum of 3 quarters · filed 2025-02-27 | $512.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | $125.86M 10-Q · filed 2023-10-26 | $259.35M derived: sum of 2 quarters · filed 2023-10-26 | $369.98M 10-Q · filed 2023-10-26 | $496.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $133.49M 10-Q · filed 2023-07-27 | $244.12M 10-Q · filed 2023-07-27 | $371.04M derived: sum of 3 quarters · filed 2024-02-22 | $482.99M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $110.63M 10-Q · filed 2023-05-04 | $237.55M derived: sum of 2 quarters · filed 2024-02-22 | $349.50M derived: sum of 3 quarters · filed 2024-02-22 | $466.71M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $126.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $238.88M derived: sum of 2 quarters · filed 2024-02-22 | $356.09M derived: sum of 3 quarters · filed 2024-02-22 | $464.49M 10-K · filed 2024-02-22 |
| 2021-09-30 | $111.95M 10-Q · filed 2022-10-27 | $229.16M derived: sum of 2 quarters · filed 2022-10-27 | $337.56M 10-Q · filed 2022-10-27 | $441.29M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $117.21M 10-Q · filed 2022-07-28 | $225.61M 10-Q · filed 2022-07-28 | $329.34M derived: sum of 3 quarters · filed 2023-02-23 | $418.58M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $108.40M 10-Q · filed 2022-04-28 | $212.12M derived: sum of 2 quarters · filed 2023-02-23 | $301.37M derived: sum of 3 quarters · filed 2023-02-23 | $385.15M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $103.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $192.97M derived: sum of 2 quarters · filed 2023-02-23 | $276.75M derived: sum of 3 quarters · filed 2023-02-23 | $357.46M 10-K · filed 2023-02-23 |
| 2020-09-30 | $89.24M 10-Q · filed 2021-10-28 | $173.03M derived: sum of 2 quarters · filed 2021-10-28 | $253.74M 10-Q · filed 2021-10-28 | $328.03M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $83.78M 10-Q · filed 2021-07-29 | $164.50M 10-Q · filed 2021-07-29 | $238.79M derived: sum of 3 quarters · filed 2022-02-24 | $304.10M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $80.71M 10-Q · filed 2021-04-29 | $155.01M derived: sum of 2 quarters · filed 2022-02-24 | $220.31M derived: sum of 3 quarters · filed 2022-02-24 | $284.73M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $74.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $139.60M derived: sum of 2 quarters · filed 2022-02-24 | $204.01M derived: sum of 3 quarters · filed 2022-02-24 | $263.63M 10-K · filed 2022-02-24 |
| 2019-09-30 | $65.31M 10-Q · filed 2020-10-29 | $129.72M derived: sum of 2 quarters · filed 2020-10-29 | $189.33M 10-Q · filed 2020-10-29 | $244.64M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $64.41M 10-Q/A · filed 2020-10-02 | $124.02M 10-Q/A · filed 2020-10-02 | $179.33M derived: sum of 3 quarters · filed 2021-02-25 | $230.39M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $59.61M 10-Q/A · filed 2020-10-02 | $114.92M derived: sum of 2 quarters · filed 2021-02-25 | $165.98M derived: sum of 3 quarters · filed 2021-02-25 | $214.74M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $55.31M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $106.36M derived: sum of 2 quarters · filed 2021-02-25 | $155.13M derived: sum of 3 quarters · filed 2021-02-25 | $201.69M 10-K · filed 2021-02-25 |
| 2018-09-30 | $51.05M 10-Q · filed 2019-10-31 | $99.82M derived: sum of 2 quarters · filed 2019-10-31 | $146.38M 10-Q · filed 2019-10-31 | $188.91M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $48.77M 10-Q · filed 2019-07-25 | $95.33M 10-Q · filed 2019-07-25 | $137.86M derived: sum of 3 quarters · filed 2020-02-27 | $178.73M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $46.56M 10-Q · filed 2019-05-02 | $89.09M derived: sum of 2 quarters · filed 2020-02-27 | $129.97M derived: sum of 3 quarters · filed 2020-02-27 | $170.72M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $42.53M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $83.40M derived: sum of 2 quarters · filed 2020-02-27 | $124.16M derived: sum of 3 quarters · filed 2020-02-27 | $160.75M 10-K · filed 2020-02-27 |
| 2017-09-30 | $40.88M 10-Q · filed 2018-10-25 | $81.63M derived: sum of 2 quarters · filed 2018-10-25 | $118.22M 10-Q · filed 2018-10-25 | $155.36M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $40.75M 10-Q · filed 2018-07-26 | $77.34M 10-Q · filed 2018-07-26 | $114.49M derived: sum of 3 quarters · filed 2019-02-28 | $153.31M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $36.59M 10-Q · filed 2018-04-26 | $73.73M derived: sum of 2 quarters · filed 2019-02-28 | $112.56M derived: sum of 3 quarters · filed 2019-02-28 | $151.50M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $37.15M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $75.97M derived: sum of 2 quarters · filed 2019-02-28 | $114.91M derived: sum of 3 quarters · filed 2019-02-28 | $151.92M 10-K · filed 2019-02-28 |
| 2016-09-30 | $38.82M 10-Q · filed 2017-10-26 | $77.77M derived: sum of 2 quarters · filed 2017-10-26 | $114.78M 10-Q · filed 2017-10-26 | $151.46M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-06-30 | $38.95M 10-Q · filed 2017-07-27 | $75.96M 10-Q · filed 2017-07-27 | $112.64M derived: sum of 3 quarters · filed 2018-02-22 | $140.17M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-03-31 | $37.01M 10-Q · filed 2017-04-27 | $73.69M derived: sum of 2 quarters · filed 2018-02-22 | $101.23M derived: sum of 3 quarters · filed 2018-02-22 | $130.22M derived: sum of 4 quarters · filed 2018-02-22 |
| 2015-12-31 | $36.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $64.22M derived: sum of 2 quarters · filed 2018-02-22 | $93.22M derived: sum of 3 quarters · filed 2018-02-22 | $116.47M 10-K · filed 2018-02-22 |
| 2015-09-30 | $27.53M 10-Q · filed 2016-11-02 | $56.53M derived: sum of 2 quarters · filed 2016-11-02 | $79.79M 10-Q · filed 2016-11-02 | $103.97M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $29.00M 10-Q · filed 2016-07-28 | $52.26M 10-Q · filed 2016-07-28 | $76.44M derived: sum of 3 quarters · filed 2017-02-23 | $96.13M derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $23.26M 10-Q · filed 2016-05-10 | $47.44M derived: sum of 2 quarters · filed 2017-02-23 | $67.13M derived: sum of 3 quarters · filed 2017-02-23 | |
| 2014-12-31 | $24.18M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $43.87M derived: sum of 2 quarters · filed 2017-02-23 | $85.61M 10-K · filed 2017-02-23 | |
| 2014-09-30 | $19.69M 10-Q · filed 2015-10-27 | $61.43M 10-Q · filed 2015-10-27 | ||
| 2013-12-31 | $67.81M 10-K · filed 2016-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |